Global Myasthenia Gravis Drugs Market Research Report 2019

Table of Contents

Executive Summary

1 Myasthenia Gravis Drugs Market Overview

• 1.1 Product Overview and Scope of Myasthenia Gravis Drugs
• 1.2 Myasthenia Gravis Drugs Segment by Type
  • 1.2.1 Global Myasthenia Gravis Drugs Production Growth Rate Comparison by Type (2014-2025)
  • 1.2.2 Anticholinesterases
  • 1.2.3 Immunosuppressants
  • 1.2.4 Intravenous Immune Globulins
• 1.3 Myasthenia Gravis Drugs Segment by Application
  • 1.3.1 Myasthenia Gravis Drugs Consumption Comparison by Application (2014-2025)
  • 1.3.2 Hospitals
  • 1.3.3 Clinics
• 1.4 Global Myasthenia Gravis Drugs Market by Region
  • 1.4.1 Global Myasthenia Gravis Drugs Market Size Region
  • 1.4.2 North America Status and Prospect (2014-2025)
  • 1.4.3 Europe Status and Prospect (2014-2025)
  • 1.4.4 China Status and Prospect (2014-2025)
  • 1.4.5 Japan Status and Prospect (2014-2025)
• 1.5 Global Myasthenia Gravis Drugs Market Size
  • 1.5.1 Global Myasthenia Gravis Drugs Revenue (2014-2025)
  • 1.5.2 Global Myasthenia Gravis Drugs Production (2014-2025)

2 Global Myasthenia Gravis Drugs Market Competition by Manufacturers

• 2.1 Global Myasthenia Gravis Drugs Production Market Share by Manufacturers (2014-2019)
• 2.2 Global Myasthenia Gravis Drugs Revenue Share by Manufacturers (2014-2019)
• 2.3 Global Myasthenia Gravis Drugs Average Price by Manufacturers (2014-2019)
• 2.4 Manufacturers Myasthenia Gravis Drugs Production Sites, Area Served, Product Types
• 2.5 Myasthenia Gravis Drugs Market Competitive Situation and Trends
  • 2.5.1 Myasthenia Gravis Drugs Market Concentration Rate
  • 2.5.2 Myasthenia Gravis Drugs Market Share of Top 3 and Top 5 Manufacturers
  • 2.5.3 Mergers & Acquisitions, Expansion

3 Global Myasthenia Gravis Drugs Production Market Share by Regions

• 3.1 Global Myasthenia Gravis Drugs Production Market Share by Regions
• 3.2 Global Myasthenia Gravis Drugs Revenue Market Share by Regions (2014-2019)
• 3.3 Global Myasthenia Gravis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
• 3.4 North America Myasthenia Gravis Drugs Production
  • 3.4.1 North America Myasthenia Gravis Drugs Production Growth Rate (2014-2019)
  • 3.4.2 North America Myasthenia Gravis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
• 3.5 Europe Myasthenia Gravis Drugs Production
  • 3.5.1 Europe Myasthenia Gravis Drugs Production Growth Rate (2014-2019)
  • 3.5.2 Europe Myasthenia Gravis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
• 3.6 China Myasthenia Gravis Drugs Production (2014-2019)
  • 3.6.1 China Myasthenia Gravis Drugs Production Growth Rate (2014-2019)
  • 3.6.2 China Myasthenia Gravis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
• 3.7 Japan Myasthenia Gravis Drugs Production (2014-2019)
  • 3.7.1 Japan Myasthenia Gravis Drugs Production Growth Rate (2014-2019)
  • 3.7.2 Japan Myasthenia Gravis Drugs Production, Revenue, Price and Gross Margin (2014-2019)

4 Global Myasthenia Gravis Drugs Consumption by Regions

• 4.1 Global Myasthenia Gravis Drugs Consumption by Regions
• 4.2 North America Myasthenia Gravis Drugs Consumption (2014-2019)
• 4.3 Europe Myasthenia Gravis Drugs Consumption (2014-2019)
• 4.4 China Myasthenia Gravis Drugs Consumption (2014-2019)
• 4.5 Japan Myasthenia Gravis Drugs Consumption (2014-2019)

5 Global Myasthenia Gravis Drugs Production, Revenue, Price Trend by Type

• 5.1 Global Myasthenia Gravis Drugs Production Market Share by Type (2014-2019)
• 5.2 Global Myasthenia Gravis Drugs Revenue Market Share by Type (2014-2019)
• 5.3 Global Myasthenia Gravis Drugs Price by Type (2014-2019)
• 5.4 Global Myasthenia Gravis Drugs Production Growth by Type (2014-2019)

6 Global Myasthenia Gravis Drugs Market Analysis by Applications

• 6.1 Global Myasthenia Gravis Drugs Consumption Market Share by Application (2014-2019)
• 6.2 Global Myasthenia Gravis Drugs Consumption Growth Rate by Application (2014-2019)

7 Company Profiles and Key Figures in Myasthenia Gravis Drugs Business

• 7.1 Flamel Technologies
  • 7.1.1 Flamel Technologies Myasthenia Gravis Drugs Production Sites and Area Served
  • 7.1.2 Myasthenia Gravis Drugs Product Introduction, Application and Specification
  • 7.1.3 Flamel Technologies Myasthenia Gravis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.1.4 Main Business and Markets Served
• 7.2 Roche
  • 7.2.1 Roche Myasthenia Gravis Drugs Production Sites and Area Served
  • 7.2.2 Myasthenia Gravis Drugs Product Introduction, Application and Specification
  • 7.2.3 Roche Myasthenia Gravis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.2.4 Main Business and Markets Served
• 7.3 Grifols
  • 7.3.1 Grifols Myasthenia Gravis Drugs Production Sites and Area Served
  • 7.3.2 Myasthenia Gravis Drugs Product Introduction, Application and Specification
  • 7.3.3 Grifols Myasthenia Gravis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.3.4 Main Business and Markets Served
• 7.4 Pfizer
  • 7.4.1 Pfizer Myasthenia Gravis Drugs Production Sites and Area Served
  • 7.4.2 Myasthenia Gravis Drugs Product Introduction, Application and Specification
  • 7.4.3 Pfizer Myasthenia Gravis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.4.4 Main Business and Markets Served
• 7.5 Shire
  • 7.5.1 Shire Myasthenia Gravis Drugs Production Sites and Area Served
  • 7.5.2 Myasthenia Gravis Drugs Product Introduction, Application and Specification
  • 7.5.3 Shire Myasthenia Gravis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.5.4 Main Business and Markets Served
• 7.6 Novartis
  • 7.6.1 Novartis Myasthenia Gravis Drugs Production Sites and Area Served
  • 7.6.2 Myasthenia Gravis Drugs Product Introduction, Application and Specification
  • 7.6.3 Novartis Myasthenia Gravis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.6.4 Main Business and Markets Served
• 7.7 Valeant
  • 7.7.1 Valeant Myasthenia Gravis Drugs Production Sites and Area Served
  • 7.7.2 Myasthenia Gravis Drugs Product Introduction, Application and Specification
  • 7.7.3 Valeant Myasthenia Gravis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.7.4 Main Business and Markets Served
• 7.8 Alexion
  • 7.8.1 Alexion Myasthenia Gravis Drugs Production Sites and Area Served
  • 7.8.2 Myasthenia Gravis Drugs Product Introduction, Application and Specification
  • 7.8.3 Alexion Myasthenia Gravis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.8.4 Main Business and Markets Served
• 7.9 Catalyst
  • 7.9.1 Catalyst Myasthenia Gravis Drugs Production Sites and Area Served
  • 7.9.2 Myasthenia Gravis Drugs Product Introduction, Application and Specification
  • 7.9.3 Catalyst Myasthenia Gravis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.9.4 Main Business and Markets Served
• 7.10 CSL
  • 7.10.1 CSL Myasthenia Gravis Drugs Production Sites and Area Served
  • 7.10.2 Myasthenia Gravis Drugs Product Introduction, Application and Specification
  • 7.10.3 CSL Myasthenia Gravis Drugs Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.10.4 Main Business and Markets Served
• 7.11 Curavac
• 7.12 Cytokinetics
• 7.13 Galencia
• 7.14 GlaxoSmithKline
• 7.15 Lupin Pharmaceuticals
• 7.16 Mitsubishi Tanabe Pharma

8 Myasthenia Gravis Drugs Manufacturing Cost Analysis

• 8.1 Myasthenia Gravis Drugs Key Raw Materials Analysis
  • 8.1.1 Key Raw Materials
  • 8.1.2 Price Trend of Key Raw Materials
  • 8.1.3 Key Suppliers of Raw Materials
• 8.2 Proportion of Manufacturing Cost Structure
• 8.3 Manufacturing Process Analysis of Myasthenia Gravis Drugs
• 8.4 Myasthenia Gravis Drugs Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers

• 9.1 Marketing Channel
  • 9.1.1 Direct Marketing
  • 9.1.2 Indirect Marketing
• 9.2 Myasthenia Gravis Drugs Distributors List
• 9.3 Myasthenia Gravis Drugs Customers

10 Market Dynamics

• 10.1 Market Trends
• 10.2 Opportunities
• 10.3 Market Drivers
• 10.4 Challenges
• 10.5 Influence Factors

11 Global Myasthenia Gravis Drugs Market Forecast

• 11.1 Global Myasthenia Gravis Drugs Production, Revenue Forecast
  • 11.1.1 Global Myasthenia Gravis Drugs Production Growth Rate Forecast (2019-2025)
  • 11.1.2 Global Myasthenia Gravis Drugs Revenue and Growth Rate Forecast (2019-2025)
  • 11.1.3 Global Myasthenia Gravis Drugs Price and Trend Forecast (2019-2025)
• 11.2 Global Myasthenia Gravis Drugs Production Forecast by Regions (2019-2025)
  • 11.2.1 North America Myasthenia Gravis Drugs Production, Revenue Forecast (2019-2025)
  • 11.2.2 Europe Myasthenia Gravis Drugs Production, Revenue Forecast (2019-2025)
  • 11.2.3 China Myasthenia Gravis Drugs Production, Revenue Forecast (2019-2025)
  • 11.2.4 Japan Myasthenia Gravis Drugs Production, Revenue Forecast (2019-2025)
• 11.3 Global Myasthenia Gravis Drugs Consumption Forecast by Regions (2019-2025)
  • 11.3.1 North America Myasthenia Gravis Drugs Consumption Forecast (2019-2025)
  • 11.3.2 Europe Myasthenia Gravis Drugs Consumption Forecast (2019-2025)
  • 11.3.3 China Myasthenia Gravis Drugs Consumption Forecast (2019-2025)
  • 11.3.4 Japan Myasthenia Gravis Drugs Consumption Forecast (2019-2025)
• 11.4 Global Myasthenia Gravis Drugs Production, Revenue and Price Forecast by Type (2019-2025)
• 11.5 Global Myasthenia Gravis Drugs Consumption Forecast by Application (2019-2025)

12 Research Findings and Conclusion

13 Methodology and Data Source

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources
• 13.3 Author List